Lifetime prevalence of cancer in Germany between 2010 and 2019: An analysis based on aggregated data
Kira Baginski, Dina Voeltz, Claudia Hornberg, Claudia Kohring, Annika Hoyer
TL;DR
This study estimates the increasing number of cancer survivors in Germany from 2010 to 2019, showing a significant rise in cancer prevalence, especially among older adults.
Contribution
The study provides the first detailed analysis of lifetime cancer prevalence in Germany using aggregated data and a partial differential equation model.
Findings
Lifetime cancer prevalence in Germany increased from 2.51 million in 2010 to over 5.07 million in 2019.
At age 85, 49% of males and 28% of females were estimated to have had cancer.
Childhood cancer prevalence was less than 0.3% among individuals under 18 years old.
Abstract
Many cancer survivors (i.e., individuals alive who have been diagnosed with cancer at some point in their lives) remain under surveillance by doctors and medical professionals regardless of the outcome of their treatment as they face the risk of recurrence and/or encounter symptoms and other health-related issues. With advancements in cancer early detection, diagnostics, and treatment strategies, along with an increasingly older population, the number of cancer survivors is steadily increasing. Since information on epidemiological indicators of cancer survivors is limited in Germany, the present study aims to estimate its prevalence between 2010 and 2019. The annual age- and sex-specific lifetime prevalence of cancer was estimated using a partial differential equation. The calculation was based on comprehensive data obtained from the Centre for Cancer Registry Data (Zentrum für…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14
Figure 15
Figure 16
Figure 17
Figure 18Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsEconomic and Financial Impacts of Cancer · Global Cancer Incidence and Screening · Health and Medical Studies